Cargando…

Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease

A rigidification strategy was applied to the preclinical candidate donecopride, an acetylcholinesterase inhibitor possessing 5-HT(4)R agonist activity. Inspired by promising bioactive benzisoxazole compounds, we have conducted a pharmacomodulation study to generate a novel series of multitarget dire...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalut, Julien, Payan, Hugo, Davis, Audrey, Lecoutey, Cédric, Legay, Rémi, Sopkova-de Oliveira Santos, Jana, Claeysen, Sylvie, Dallemagne, Patrick, Rochais, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033111/
https://www.ncbi.nlm.nih.gov/pubmed/32080261
http://dx.doi.org/10.1038/s41598-020-59805-7
_version_ 1783499592741945344
author Lalut, Julien
Payan, Hugo
Davis, Audrey
Lecoutey, Cédric
Legay, Rémi
Sopkova-de Oliveira Santos, Jana
Claeysen, Sylvie
Dallemagne, Patrick
Rochais, Christophe
author_facet Lalut, Julien
Payan, Hugo
Davis, Audrey
Lecoutey, Cédric
Legay, Rémi
Sopkova-de Oliveira Santos, Jana
Claeysen, Sylvie
Dallemagne, Patrick
Rochais, Christophe
author_sort Lalut, Julien
collection PubMed
description A rigidification strategy was applied to the preclinical candidate donecopride, an acetylcholinesterase inhibitor possessing 5-HT(4)R agonist activity. Inspired by promising bioactive benzisoxazole compounds, we have conducted a pharmacomodulation study to generate a novel series of multitarget directed ligands. The chemical synthesis of the ligand was optimized and compounds were evaluated in vitro against each target and in cellulo. Structure-activity relationship was supported by docking analysis in human acetylcholinesterase binding site. Among the synthesized compounds, we have identified a novel hybrid 32a (3-[2-[1-(cyclohexylmethyl)-4-piperidyl]ethyl]-4-methoxy-1,2-benzoxazole) able to display nanomolar acetylcholinesterase inhibitory effects and nanomolar Ki for 5-HT(4)R.
format Online
Article
Text
id pubmed-7033111
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70331112020-02-27 Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease Lalut, Julien Payan, Hugo Davis, Audrey Lecoutey, Cédric Legay, Rémi Sopkova-de Oliveira Santos, Jana Claeysen, Sylvie Dallemagne, Patrick Rochais, Christophe Sci Rep Article A rigidification strategy was applied to the preclinical candidate donecopride, an acetylcholinesterase inhibitor possessing 5-HT(4)R agonist activity. Inspired by promising bioactive benzisoxazole compounds, we have conducted a pharmacomodulation study to generate a novel series of multitarget directed ligands. The chemical synthesis of the ligand was optimized and compounds were evaluated in vitro against each target and in cellulo. Structure-activity relationship was supported by docking analysis in human acetylcholinesterase binding site. Among the synthesized compounds, we have identified a novel hybrid 32a (3-[2-[1-(cyclohexylmethyl)-4-piperidyl]ethyl]-4-methoxy-1,2-benzoxazole) able to display nanomolar acetylcholinesterase inhibitory effects and nanomolar Ki for 5-HT(4)R. Nature Publishing Group UK 2020-02-20 /pmc/articles/PMC7033111/ /pubmed/32080261 http://dx.doi.org/10.1038/s41598-020-59805-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lalut, Julien
Payan, Hugo
Davis, Audrey
Lecoutey, Cédric
Legay, Rémi
Sopkova-de Oliveira Santos, Jana
Claeysen, Sylvie
Dallemagne, Patrick
Rochais, Christophe
Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title_full Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title_fullStr Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title_full_unstemmed Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title_short Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT(4) receptors activities for the treatment of Alzheimer’s disease
title_sort rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-ht(4) receptors activities for the treatment of alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033111/
https://www.ncbi.nlm.nih.gov/pubmed/32080261
http://dx.doi.org/10.1038/s41598-020-59805-7
work_keys_str_mv AT lalutjulien rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT payanhugo rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT davisaudrey rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT lecouteycedric rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT legayremi rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT sopkovadeoliveirasantosjana rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT claeysensylvie rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT dallemagnepatrick rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease
AT rochaischristophe rationaldesignofnovelbenzisoxazolederivativeswithacetylcholinesteraseinhibitoryandserotoninergic5ht4receptorsactivitiesforthetreatmentofalzheimersdisease